(“In an ‘Allo or Bust’ Market, What’s Rising to the Top of the Shelf?”)

From Cancer Progress 2020

Moderator: Michael Rice, SVP, BioConsulting, Head of Advanced Therapeutics and Rare Diseases, Lumanity


  • Robert Ang, MD, MBA, President & CEO, Vor BioPharma Inc.
  • Jim Beitel, MD, PhD, SVP, Corporate Development, Fate Therapeutics Inc
  • Thomas J. Farrell, President & CEO, Artiva Biotherapeutics
  • Maksim Mamonkin PhD, Assistant Professor, Pathology & Immunology Center for Cell and Gene Therapy, Baylor College of Medicine
  • Gary Shapiro, PhD, Director of Immuno-Oncology Research, Takeda Pharmaceuticals
  • Arthur Stril, VP Corporate Development, Cellectis